Home › Research › Treatments
Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation)
Biogen Inc. press release, 2024-01-31
Topic: Amyloid, tau and blood-test diagnosis
On January 31, 2024, Biogen announced it would discontinue development and sales of Aduhelm (aducanumab) and end the mandatory post-approval ENVISION confirmatory trial, redirecting resources to lecanemab (Leqembi) and other pipeline drugs, including two tau-targeting compounds (BIIB080, BIIB113). Biogen stated the decision was not driven by new safety or efficacy concerns, but by the cost of continuing the confirmatory trial and lack of interested commercial partners.
Key findings
- Aduhelm's development and sale is fully discontinued; the FDA-mandated ENVISION confirmatory trial was terminated
- Biogen said the decision was 'not related to any safety or efficacy concerns' but reflected strategic/financial factors
- Resources redirected to Leqembi and to tau-targeting candidates BIIB080 and BIIB113
Why it matters
Biogen discontinued Aduhelm and ended the FDA-mandated ENVISION confirmatory trial, stating the decision was not driven by new safety or efficacy concerns but by cost and lack of commercial partners. Resources were redirected to lecanemab and to tau-targeting candidates BIIB080 and BIIB113.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcompany announcement
Limitations
Company press release, not primary research; Biogen stated the decision was not related to safety/efficacy concerns but to cost and lack of commercial partners for the required confirmatory trial.
How this study scored 11/100
Press release — not a study. It scored 11 on the same rubric, which is below the 16 cap we apply to non-peer-reviewed sources. Scored zero for study design, sample size, effect reported, studied in people, randomised / blinded and indexed in PubMed because the record does not state it. We have no data on strength of evidence, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 7 of the 61 points we could judge it on, which is 11 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Biogen Inc. press release) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | Design recorded as “company announcement”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 1 / 10 | Press release — not a study. Named source is a company press release. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 7 / 61 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 7 of the 61 points we could judge it on is 11 out of 100. |
| Total | 11 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. This record has no authors, DOI, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation). (2024). Biogen Inc. press release.
Vancouver
Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation). Biogen Inc. press release. 2024.
BibTeX
@article{study2024-49a9a379,
title = {{Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation)}},
journal = {Biogen Inc. press release},
year = {2024}
}